TLX News: Illuccix® Receives European Approval - 17th Jan 2025, 9:14am

[annb0t]

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP).(PRNewsfoto/Telix Pharmaceuticals Limited)

This signific...

>>> Read more: Illuccix® Receives European Approval